It will be too early too tell in their financials. We might get some commentary around margins and competition but I doubt it. MND or LYL haven't announced any contract wins either so I might be jumping at shadows.
When you look at the ROE for the various players you can see the attraction for MND and LYL.
ROE:
2011 2012 2013 2014 2015 2016
MND 49.2 51.3 50.7 38.2 28.7 18.2
LYL 35.3 37.1 31.9 6.2 -1.5 6.0
GNG 51.7 31.1 18.3 30.4 26.6 37.2
But ROE is a function of industry competitiveness (as well as obvious cyclicality in this industry).
Mr Market doesn't seem to be as worried as I am though. Price / book value for GNG is currently 4.73x on my numbers. While that is ok for a company that can maintain their high ROE it is much higher than it has been historically facing into what is arguably more competition from some very respected players.
Price / Book:
Current 4.73x
2016 2.90x
2015 2.79x
2014 2.25x
2013 1.67x
2012 3.20x
- Forums
- ASX - By Stock
- GNG
- Trading significantly under market value?
Trading significantly under market value?, page-19
Featured News
Add GNG (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.19 |
Change
0.020(0.92%) |
Mkt cap ! $293.0M |
Open | High | Low | Value | Volume |
$2.17 | $2.20 | $2.17 | $272.4K | 124.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 697 | $2.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.20 | 38381 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1629 | 1.695 |
1 | 1629 | 1.690 |
2 | 2129 | 1.685 |
1 | 5500 | 1.680 |
2 | 18283 | 1.670 |
Price($) | Vol. | No. |
---|---|---|
1.715 | 2443 | 1 |
1.720 | 2444 | 1 |
1.735 | 15000 | 1 |
1.790 | 3500 | 1 |
1.800 | 15892 | 2 |
Last trade - 16.10pm 25/11/2024 (20 minute delay) ? |
Featured News
GNG (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online